糖原合成酶1（GYS1）、巨噬细胞移动抑制因子（MIF）和原癌基因（MYC）的过表达与骨髓增生异常综合征和急性髓系白血病的不良预后及对阿扎胞苷反应不佳相关。
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
作者信息
Falantes Jose F, Trujillo Pablo, Piruat Jose I, Calderón Cristina, Márquez-Malaver Francisco J, Martín-Antonio Beatriz, Millán Africa, Gómez Marina, González Jose, Martino Maria L, Montero Isabel, Parody Rocío, Espigado Ildefonso, Urbano-Ispizua Alvaro, Pérez-Simón Jose A
机构信息
Department of Haematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
出版信息
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.
BACKGROUND
The prognosis of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) is very heterogeneous.
PATIENTS AND METHODS
We analyzed the prognostic value of several genes in a cohort of 85 MDS and AML patients.
RESULTS
Overexpression of glycogen synthase 1 and macrophage migration inhibitory factor genes had an adverse outcome in multivariate analysis (P = .003 and P < .001, respectively). Furthermore, the higher expression of myelocytomatosis oncogene was associated with a lower response to azacitidine (P = .03).
CONCLUSION
In the current study we identified a specific gene expression profile as prognostic factors for response to azacitidine and survival in MDS and AML.
背景
骨髓增生异常综合征（MDS）和急性髓系白血病（AML）的预后差异很大。
患者与方法
我们分析了85例MDS和AML患者队列中多个基因的预后价值。
结果
在多变量分析中，糖原合酶1和巨噬细胞迁移抑制因子基因的过表达具有不良预后（分别为P = 0.003和P < 0.001）。此外，髓细胞瘤致癌基因的高表达与对阿扎胞苷的反应较低相关（P = 0.03）。
结论
在本研究中，我们确定了一种特定的基因表达谱作为MDS和AML中阿扎胞苷反应和生存的预后因素。
Zotero 插件